Effective Management of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Tips for the Practicing Community-based Clinician


Stella E. Lee, MD

Section Chief, Rhinology Division of Otolaryngology—Head and Neck Surgery Department of Surgery Brigham and Women's Hospital Harvard Medical School Boston, MA

Disclosures
 Dr. Lee is a consultant for AstraZeneca, GlaxoSmithKline, Genentech, Lyra Therapeutics, OptiNose and Sanofi/Regeneron.
During the program, the faculty may mention the use of medications for FDA-approved and non-approved indications
All relevant financial relationships have been mitigated.
This activity is supported by an independent medical education grant from
Regeneron Pharmaceuticals, Inc. and Sanofi

Learning Objectives

- Identify strategies to manage CRSwNP that are aligned with evidencebased guidelines
- Discuss the clinical evidence for novel, emerging therapeutic agents for the treatment of CRSwNP
- Describe strategies to effectively select treatment based on patientspecific factors and expert guidance





CRSwNP Biomarkers

• No accurate biomarkers for CRSwNP currently available

- Type 2 inflammation often predominates in CRSwNP
 - Associated with elevated levels of eosinophils and type 2 cytokines, including IL-4, IL-5, and IL-13, IgE
- Modalities utilized to obtain potential biomarkers
 - Sinus-tissue biopsy or mucus may be most accurate in assessing local processes underlying inflammation
 - Peripheral blood does not always reflect local nasal inflammatory processes
 - With nasal lavage, inconsistent correlation between cytokines in nasal secretions compared with tissue

NS = nasal secretions; PB = peripheral blood; TSLP = thymic stromal lymphoprotein. Workman AD, et al. Immunol Allergy Clin North Am. 2018;38:679-692.





Outcomes of Dupilumab vs Endoscopic Sinus Surgery Inclusion criteria 2015 2021 • Adults (>18 years) • Dupilumab treatment (with 23 months Dupilumab 300 mg Q2W SC N = 108 follow-up) or bilateral total FESS (with **Bilateral complete FESS** concomitant use of topical steroids) **Baseline characteristics** Matching criteria NPS (mean age) (mean) (mean score) (mean number of) • SNOT-22 • Age 6.3 NPS • Sex (mean age) (mean) (mean score) (mean number of) • Ethnicity

CRSwNP = chronic rhinosinusitis with nasal polyps; FESS = functional endoscopic sinus surgery; NPS = nasal polyp score; q2w = every 2 weeks; SC = subcutaneous; SNOT-22 = Sino-Nasal Outcome Test-22. Dharmarajan H, et al. Int Forum Allergy Rhinol. 2022;1-10.



Corticosteroids: Evidence and Use for CRSwNP Topical: Standard Delivery

Intranasal corticosteroids (standard delivery) for CRSwNP

Evidence: A (Level 1: 2 studies, Level 2: 5 studies)

Benefit: Improved symptoms, endoscopic appearances, polyp size, and QoL, objective tests of olfaction, airway analysis (NPIF) and polyp recurrence but the magnitude of the clinical effect is small

Harm: Epistaxis, nasal irritation, headache


Cost: Moderate depending on preparation


<u>Intervention</u>: Topical nasal CS (sprays or drops) are recommended for CRSwNP before or after sinus surgery; consideration for twice daily dosing or additional short-term corticosteroid drop if initial treatment effect is small


NPIF = nasal peak inspiratory flow. Orlandi R, et al. *Int Forum Allergy Rhinol*. 2021;11(3):213-739.

Corticosteroids: Evidence and Use for CRSwNP Topical: Nonstandard Delivery ntranasal corticosteroids (nonstandard delivery) for CRSwNP	
Corticost	eroid irrigation: A (Level 1: 5 studies, level 3: 1 study)
Exhalatio	on delivery: A (Level 1: 4 studies)
	tion/nebulization: A (Level 1: 4 studies)
	iection: N/A (Level 1: 1 study)
Benefit:	
Corticost	eroid irrigation: Benefit over INCS
Exhalatio	on delivery: Benefit only over placebo
Atomiza	tion/nebulization: Benefit over INCS
Direct in	iection: Potential avoidance of oral corticosteroid
Harm: Som	e evidence of systemic absorption with first generation CS especially with multiple modalities of
therapy	
Cost: Mode	erate; exhalation system costs are significantly higher than standard therapy
	<u>m</u> : Following sinus surgery, those patients with CRSwNP that have moderate to severe disease or ontrolled with simple INCS should be offered CS irrigation and/or atomized delivery


Orlandi R, et al. Int Forum Allergy Rhinol. 2021;11(3):213-739.









Gevaert P, et al. J Allergy Clin Immunol. 2020;146:595-605.









ATPO Too busy. There are figures available. Anju Tripathi Peters, 2023-07-20T22:04:48.227

DG0 0 Added figures Debra Gordon, 2023-07-27T15:00:46.917

SINUS-24/SINUS-52: Conclusions

- In patients with severe uncontrolled CRSwNP, dupilumab as add-on to MFNS
 - Significantly improved NP size, sinus opacification, and CRS symptoms
 - Reduced anosmia and improved HRQoL
 - Improved all outcome measures, which were noted at first assessment timepoint and continued to improve across 52-week treatment period
- Dupilumab reduced SCS use and need for NP surgery
- Dupilumab improved lung function and asthma control in patients with CRSwNP with comorbid asthma, a difficult-to-treat patient population
- Compared with 300 mg Q2W to Q4W, the 300 mg Q2W regimen had
 - Better sustained improvements in objective measures of NPS and LMK-CT scan score
 - Fewer breakthrough TEAEs of worsening of nasal polyps, asthma, and sinusitis

Bachert C, et al. Lancet. 2019;394:1638-1650.

